OpenBit ResearchOpenBit
中文

What's driving Arrowhead Pharmaceuticals (ARWR)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Can ARO-DIMER-PA Translate Dual Gene Silencing Into Cardiometabolic Benefit?

Why it matters now

ARO-DIMER-PA clinical efficacy and cardiometabolic portfolio fit can affect Arrowhead Pharmaceuticals' development prospects and valuation.

Next checkpoint

ARWR earnings (expected 2026-11-24)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to ARWR, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

The silencing is not durable or the observed gene silencing fails to translate into sustained lipid improvement.

Research drivers

  • Can ARO-DIMER-PA Translate Dual Gene Silencing Into Cardiometabolic Benefit?

    Bullish · Cooling · Updated

    The interim Phase 1/2a data show substantial dual-gene silencing and associated reductions across LDL-C, triglycerides, non-HDL cholesterol, and ApoB, supporting an active early clinical read while durability and later-stage benefit remain to be established.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • Arrowhead Pharmaceuticals reported mean maximal single-dose reductions of 72% in serum PCSK9 and 88% in APOC3.

    Relayed by: Benzinga · Event date on record:

  • Arrowhead Pharmaceuticals reported that ARO-DIMER-PA treatment led to LDL-C reduction of 54%, triglyceride reduction of 73%, non-high-density lipoprotein cholesterol reduction of 61%, and Apolipoprotein B reduction of 50%.

    Relayed by: Benzinga · Event date on record:

  • Arrowhead CEO Chris Anzalone said ARO-DIMER-PA fits strategically with Arrowhead’s focus on cardiometabolic diseases and is complemented by the company’s existing portfolio.

    Relayed by: Benzinga · Event date on record:

  • Arrowhead Pharmaceuticals said ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule.

    Relayed by: Benzinga · Event date on record:

  • Arrowhead Pharmaceuticals reported interim topline clinical data from a Phase 1/2a trial evaluating ARO-DIMER-PA for atherosclerotic cardiovascular disease due to mixed hyperlipidemia.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.